Amy Rose

4.2k total citations
47 papers, 1.4k citations indexed

About

Amy Rose is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Amy Rose has authored 47 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 12 papers in Cancer Research and 11 papers in Molecular Biology. Recurrent topics in Amy Rose's work include Cancer Immunotherapy and Biomarkers (13 papers), Cutaneous Melanoma Detection and Management (9 papers) and Immunotherapy and Immune Responses (7 papers). Amy Rose is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Cutaneous Melanoma Detection and Management (9 papers) and Immunotherapy and Immune Responses (7 papers). Amy Rose collaborates with scholars based in United States, Canada and Switzerland. Amy Rose's co-authors include Iman Osman, Eva Hernando, David J. Goldberg, Jan Zakrzewski, Douglas Hanniford, Ilana Belitskaya‐Lévy, Miguel F. Segura, David Polsky, Richard L. Shapiro and Farbod Darvishian and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Amy Rose

46 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy Rose United States 15 780 528 363 171 168 47 1.4k
Luís A. Corchete Spain 22 820 1.1× 294 0.6× 488 1.3× 109 0.6× 153 0.9× 78 1.5k
Francesca Collina Italy 22 680 0.9× 428 0.8× 581 1.6× 141 0.8× 220 1.3× 49 1.3k
Luigia Stefania Stucci Italy 21 642 0.8× 255 0.5× 759 2.1× 162 0.9× 482 2.9× 46 1.5k
Tsuyoshi Hata Japan 18 499 0.6× 215 0.4× 428 1.2× 110 0.6× 243 1.4× 76 1.4k
Anupma Nayak United States 20 416 0.5× 379 0.7× 462 1.3× 226 1.3× 147 0.9× 62 1.1k
José A. Figueroa United States 23 708 0.9× 285 0.5× 439 1.2× 114 0.7× 303 1.8× 57 1.4k
Le Qu China 20 884 1.1× 644 1.2× 234 0.6× 415 2.4× 107 0.6× 61 1.4k
Roger Mouawad France 21 523 0.7× 177 0.3× 308 0.8× 155 0.9× 208 1.2× 57 968
Gabriela Motyckova United States 13 995 1.3× 270 0.5× 408 1.1× 175 1.0× 209 1.2× 19 1.5k

Countries citing papers authored by Amy Rose

Since Specialization
Citations

This map shows the geographic impact of Amy Rose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Rose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Rose more than expected).

Fields of papers citing papers by Amy Rose

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Rose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Rose. The network helps show where Amy Rose may publish in the future.

Co-authorship network of co-authors of Amy Rose

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Rose. A scholar is included among the top collaborators of Amy Rose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Rose. Amy Rose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zang, Yan, Hong Wang, Cindy Sander, et al.. (2024). A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma.. Journal of Clinical Oncology. 42(16_suppl). TPS9600–TPS9600. 1 indexed citations
2.
3.
Schwartz, Marc, Howard M. Dubner, Corey A. Hewitt, et al.. (2023). Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients. Melanoma Research. 33(2). 136–148. 1 indexed citations
4.
Huang, Lin, Yan Lin, Amy Rose, et al.. (2019). Association of baseline neutrophil-to-lymphocyte ratio (NLR) with response and survival in advanced melanoma (MEL) receiving PD-1 inhibitors.. Journal of Clinical Oncology. 37(15_suppl). 9571–9571.
5.
Kirkwood, John M., Shivendra V. Singh, Yan Lin, et al.. (2016). Dose-response evaluation of brocolli sprout extract sulforaphane (BSE-SFN) in melanoma patients (Pts) with atypical/dysplastic nevi (A/DN).. Journal of Clinical Oncology. 34(15_suppl). e21022–e21022. 7 indexed citations
6.
Rose, Amy, Kevin P. Boyd, S. Meehan, & Jo‐Ann Latkowski. (2013). Lichen sclerosus et atrophicus. Dermatology Online Journal. 19(12). 20714–20714. 5 indexed citations
7.
Brown, Catherine, Linda Dodds, Janet Bryanton, et al.. (2013). Rates and determinants of exclusive breastfeeding in first 6 months among women in Nova Scotia: a population-based cohort study. CMAJ Open. 1(1). E9–E17. 45 indexed citations
8.
Rose, Amy & Doris Day. (2012). Esthetic Rejuvenation of the Temple. Clinics in Plastic Surgery. 40(1). 77–89. 20 indexed citations
9.
Rose, Amy, Laura Poliseno, Jinhua Wang, et al.. (2011). Integrative Genomics Identifies Molecular Alterations that Challenge the Linear Model of Melanoma Progression. Cancer Research. 71(7). 2561–2571. 56 indexed citations
10.
Hatcher, David, Paul J. Christos, Amy Rose, et al.. (2011). Impact of race on survival in patients with clinically nonmetastatic prostate cancer who deferred primary treatment. Cancer. 118(12). 3145–3152. 14 indexed citations
11.
Rose, Amy, Paul J. Christos, Richard L. Shapiro, et al.. (2011). Clinical Relevance of Detection of Lymphovascular Invasion in Primary Melanoma Using Endothelial Markers D2-40 and CD34. The American Journal of Surgical Pathology. 35(10). 1441–1449. 46 indexed citations
12.
Michelle, W., Stefano Monni, Amy Rose, et al.. (2011). A High Proliferative Index of Recurrent Melanoma Is Associated with Worse Survival. Oncology. 80(3-4). 181–187. 14 indexed citations
13.
Rose, Amy, Marie Léger, Julie Chu, & S. Meehan. (2011). Cheilitis granulomatosa. Dermatology Online Journal. 17(10). 15–15. 7 indexed citations
14.
Segura, Miguel F., Ilana Belitskaya‐Lévy, Amy Rose, et al.. (2010). Melanoma MicroRNA Signature Predicts Post-Recurrence Survival. Clinical Cancer Research. 16(5). 1577–1586. 173 indexed citations
15.
Zakrzewski, Jan, Amy Rose, Paul J. Christos, et al.. (2010). Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post‐brain metastases survival. Cancer. 117(8). 1711–1720. 76 indexed citations
16.
Rose, Amy, Jaya M. Satagopan, Carole Oddoux, et al.. (2010). Copy number and gene expression differences between African American and Caucasian American prostate cancer. Journal of Translational Medicine. 8(1). 70–70. 47 indexed citations
17.
Rose, Amy, Guimin Wang, Douglas Hanniford, et al.. (2010). Clinical relevance of SKP2 alterations in metastatic melanoma. Pigment Cell & Melanoma Research. 24(1). 197–206. 43 indexed citations
18.
Rose, Amy, et al.. (2010). Outcomes of Patients Lost to Followup After Mid Urethral Synthetic Slings—Successes or Failures?. The Journal of Urology. 183(4). 1455–1458. 15 indexed citations
19.
Segura, Miguel F., Douglas Hanniford, Sílvia Menéndez, et al.. (2009). Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proceedings of the National Academy of Sciences. 106(6). 1814–1819. 451 indexed citations
20.
Rose, Amy, Christopher K. Payne, & Kathryn J. Azevedo. (2005). Pilot study of the feasibility of in‐office bladder distention using electromotive drug adminstration (EMDA). Neurourology and Urodynamics. 24(3). 254–260. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luís A. Corchete Breakdown of academic impact, for papers by Francesca Collina Breakdown of academic impact, for papers by Luigia Stefania Stucci Breakdown of academic impact, for papers by Tsuyoshi Hata Breakdown of academic impact, for papers by Anupma Nayak Breakdown of academic impact, for papers by José A. Figueroa Breakdown of academic impact, for papers by Le Qu Breakdown of academic impact, for papers by Roger Mouawad Breakdown of academic impact, for papers by Gabriela Motyckova
Rankless by CCL
2026